FDA Clears STARMED RFA, Ushering in a New Era for Thyroid Nodule Treatment

SEOUL, South Korea – July 01, 2026 – The landscape of thyroid care in the United States is poised for a significant transformation. South Korean medical device firm STARMED has secured a landmark 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its radiofrequency ablation (RFA) system. Effective May 26, 2026, this clearance is the first and only one of its kind, specifically indicated for the percutaneous ablation of benign thyroid nodules in adults.

For the estimated 65% of the U.S. population affected by thyroid nodules, this regulatory milestone signals the arrival of a validated, minimally invasive alternative to the long-standing options of watchful waiting or surgical removal. The clearance (K252833) provides a clear regulatory pathway for a procedure that has been widely practiced in Asia and Europe for years, finally bringing its benefits to the American healthcare system with official FDA backing.

A Regulatory Landmark with Clinical Precision

The true significance of this clearance lies in its specificity. Unlike previous approvals for general soft-tissue ablation, STARMED's indication explicitly names the procedure (ultrasound-guided percutaneous ablation), the anatomy (thyroid nodules), the patient population (adults), and the clinical eligibility criteria. This level of detail is a game-changer for physicians and healthcare institutions.

"This clearance represents an important milestone for physicians and healthcare institutions evaluating thyroid radiofrequency ablation," said Henry Shin, CEO of STARMED, in the company's announcement. "By specifically identifying the procedure, anatomy, patient population, and clinical criteria, the indication provides clear regulatory alignment for the use of our system in eligible benign thyroid nodules."

This regulatory clarity is expected to streamline the adoption process within hospitals. It simplifies institutional value analysis reviews and aligns device labeling directly with clinical evidence and established CPT coding pathways for thyroid RFA. For practitioners, it removes the ambiguity that can surround the use of devices for off-label applications, providing a solid foundation for building a thyroid RFA program.

The cleared system includes the STAR RF Electrode, engineered for precision, and the VIVA RF Electrode, which features an adjustable active tip allowing clinicians to customize the ablation zone to the size of the nodule. This technological refinement, coupled with the specific indication, empowers endocrinologists and interventional radiologists to treat patients with a higher degree of confidence and regulatory assurance.

Redefining Patient Care for a Common Condition

For patients with symptomatic or cosmetically concerning benign thyroid nodules, the primary intervention has traditionally been surgery, often involving a partial or total thyroidectomy. While effective, surgery requires general anesthesia, carries risks of scarring and vocal cord damage, and can lead to hypothyroidism, necessitating lifelong hormone replacement therapy. STARMED's RFA technology offers a starkly different patient experience.

The procedure is a minimally invasive, outpatient treatment performed under local anesthesia. Using ultrasound guidance, a physician inserts a thin electrode into the nodule and uses radiofrequency energy to generate heat, destroying the targeted tissue. The nodule then shrinks over time, relieving compressive symptoms and cosmetic concerns while preserving the healthy surrounding thyroid tissue and its function.

The FDA's decision was supported by a robust body of evidence, including a systematic literature review of 42 peer-reviewed publications. These studies consistently demonstrated a volume reduction ratio (VRR) of 50% or more at six months—the clinical benchmark for meaningful symptom relief. Some studies have reported volume reductions as high as 80-90% a year post-procedure.

Critically, the clearance also covers autonomously functioning thyroid nodules (AFTNs), or "hot nodules," under 10 mL in volume. These nodules can cause hyperthyroidism, and RFA has shown significant promise in resolving the condition by normalizing hormone levels, offering a powerful alternative to radioactive iodine therapy or surgery for eligible patients.

Two Decades in the Making: STARMED's Path to U.S. Approval

This FDA clearance is not an overnight success but the culmination of more than two decades of focused innovation. As Mr. Shin noted, the approval "reflects more than two decades of thyroid-focused technology development and physician collaboration." STARMED's deep roots in this specific clinical area are undeniable; its equipment was used in the world's first thyroid RFA procedure in South Korea back in June 2002.

The company has been a driving force in the field, developing the world's first thyroid-dedicated RFA electrode in 2009. Its commitment extends beyond technology to education and collaboration. The firm supports thyroid RFA training centers in over ten countries, fostering a global community of skilled practitioners. This dedication to technique refinement and education is reflected in the more than 300 peer-reviewed clinical publications that reference its technologies.

With its products already available in over 70 countries, STARMED is a global leader in thermal ablation. This U.S.-specific clearance represents a strategic anchoring in one of the world's largest healthcare markets, leveraging its extensive international experience to meet a significant unmet need.

The Ripple Effect on the U.S. Medtech Landscape

STARMED's achievement sets a new precedent in the U.S. medical device market. By securing an indication with such high specificity, the company has raised the bar for competitors and demonstrated the value of a targeted regulatory strategy. This move provides a distinct competitive advantage, positioning its RFA system as the go-to, FDA-cleared solution for thyroid nodule ablation.

"Having a specific indication from the FDA is a powerful catalyst," commented one interventional radiologist not affiliated with the company. "It moves a technology from being a novel or off-label option to a standard of care. It gives physicians the confidence to recommend it and helps persuade hospital administrators and payers of its legitimacy and value."

The clearance may also accelerate the development of U.S.-based clinical practice guidelines, particularly for the treatment of AFTNs, where a formal consensus has been lacking. With a clearly approved device and indication, professional societies like the American Thyroid Association and the Society of Interventional Radiology have a stronger basis upon which to build standardized protocols, further integrating RFA into mainstream clinical practice.

For the millions of Americans living with benign thyroid nodules, this news represents more than just a regulatory filing; it signifies the dawn of a new, less invasive, and gland-preserving era in thyroid health management.